Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
16 oct. 2024 07h30 HE
|
Cytokinetics, Incorporated
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 oct. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate...
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
02 oct. 2024 16h00 HE
|
Cytokinetics, Incorporated
Company Leadership to Discuss Cardiac Myosin Modulation, Specialty Cardiology Programs and Commercial Launch Preparations SOUTH SAN FRANCISCO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) --...
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
30 sept. 2024 09h20 HE
|
Cytokinetics, Incorporated
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists Results Simultaneously Published in the Journal of the...
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
27 sept. 2024 11h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
24 sept. 2024 07h30 HE
|
Cytokinetics, Incorporated
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4th, 2024 SOUTH SAN...
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
19 sept. 2024 16h00 HE
|
Cytokinetics, Incorporated
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE...
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
09 sept. 2024 07h30 HE
|
Cytokinetics, Incorporated
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,...
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
05 sept. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 sept. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it granted stock options to purchase an aggregate of...